1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Generic Drug Opportunity Assessment : Ambrisanten (Letairis)

Generic Drug Opportunity Assessment : Ambrisanten (Letairis)

  • January 2014
  • -
  • Greystone Research Associates

Greystone Research Associates has identified a branded drug that represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy. Details of our findings are contained in an insightful assessment, the highlights if which are presented below.

The Brand

Ambrisentan (brand name Letairis) is a endothelin receptor antagonist indicated for treating pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO Class II or III symptoms.. The brand drug owner is Gilead Science. The rights to the product are partially sublicensed to GlaxoSmithKline, which markets anbrisentan as Volibris, for PAH in territories outside of the United States. In 2008, Glaxo received marketing authorization from the EMA for Volibris in Europe.

The Drug

Endothelin receptor antagonists inhibit the binding of endothelin, a vasoconstrictive peptide, to its receptors on smooth muscle cells which results in vasodilation. The activation of the endothelin system plays a critical role in chronic cardiovascular diseases, such as pulmonary hypertension, and in acute cardiovascular conditions, such as right heart failure and cerebral vasospasm, a constriction of blood vessels in the brain following subarachnoid hemorrhage. It is also implicated in connective tissue diseases such as scleroderma and pulmonary fibrosis.

The Market

Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterized by high blood pressure in the arteries that funnel blood from the heart to the lungs. Although Pulmonary arterial hypertension is a rare disease, with an estimated prevalence of 15-50 cases per million, the prevalence of PAH in certain at-risk groups is substantially higher.

The Opportunity

With patents expiring for two of the top three drug brands having recently expired or expiring in the near future, generic drugs are set to have a significant impact on the therapeutic market for PAH. The patents for Letairis are not held by Gilead but are held by third parties. Gilead acquired the exclusive rights to the applicable patents in the agreements executed with these third parties. Letairis has been granted exclusivity by the FDA under exclusivity code ODE (Orphan Drug Exclusivity). This exclusivity expires on June 15, 2014.

Therapeutic Sector P (IV) Activity

The antihypertensive segment of the cardiovascular drug sector has been quite active, with P (IV) certifications averaging about four per year since 2004. This trend reflects the continuing healthcare challenges associated with hypertension as well as the fragmented therapeutic environment. We expect this trend to continue through 2017, as brand drugs lose exclusivity and patent protection.

Market Dynamics

In terms of the overall market for PAH therapeutics, we expect the dominant position of oral solid dosage forms to diminish on a total revenue basis as current and forecast future early generic drug market entries put pressure on average dosage form drug pricing. The net effect will reduce total oral solid dosage form revenue as a percent of total segment revenue from 76% in 2012 to 52% in 2018.

Generic Revenue Opportunity

We are predicting that the ANDA first-filer entering the market in will capture of the total global market for abrisanten drugs for the treatment of PAH in calendar year . The majority of sales will come during the 180-day exclusivity period, at a price approximately of the brand price.

Report Highlights

Letairis – The Brand
Ambrisentan – The Drug
Ambrisentan – The Market
Ambrisentan – The Opportunity
Ambrisentan Patents and Exclusivity
Therapeutic Class P4 Certifications
Generic Revenue Opportunity
Business Risk Assessment
First-to-File – Probabilistic Scenario

Table Of Contents

Generic Drug Opportunity Assessment : Ambrisanten (Letairis)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Softgel Capsules Market Analysis & Trends - Application(Health supplement, Vitamins & Dietary Supplements, CardiovascularDrugs, Anti-Inflammatory Drugs and Antibiotic & Antibacterial Drugs), End-User

Softgel Capsules Market Analysis & Trends - Application(Health supplement, Vitamins & Dietary Supplements, CardiovascularDrugs, Anti-Inflammatory Drugs and Antibiotic & Antibacterial Drugs), End-User

  • $ 4200
  • Industry report
  • November 2016
  • by Accuray Research LLP

The Global Softgel Capsules Market is poised to grow at a CAGR of around 5.4% over the next decade to reach approximately $316.6 billion by 2025. Some of the prominent trends that the market is witnessing ...

Global and Chinese Weakly Basic Styrene Type Anion Exchange Resin Industry, 2016 Market Research Report

Global and Chinese Weakly Basic Styrene Type Anion Exchange Resin Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese Weakly Basic Styrene Type Anion Exchange Resin Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Weakly Basic ...

Global and Chinese Weakly Basic Anion Exchange Resin Epoxy System Industry, 2016 Market Research Report

Global and Chinese Weakly Basic Anion Exchange Resin Epoxy System Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese Weakly Basic Anion Exchange Resin Epoxy System Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Weakly Basic ...


Download Unlimited Documents from Trusted Public Sources

Therapy and Cardiovascular Drug Market in Europe

  • November 2016
    6 pages
  • Therapy  

    Cardiovascular ...  

    ACE Inhibitor  

  • Europe  

View report >

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Cardiovascular Drug and Hormone Market in the US

  • October 2016
    5 pages
  • Cardiovascular ...  

    Hormone  

  • United States  

    North America  

View report >

Therapy Market

2 months ago

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.